US2443266A
(en)
*
|
1944-09-02 |
1948-06-15 |
Bendix Aviat Corp |
Commutator brush holder
|
US3117142A
(en)
|
1961-03-01 |
1964-01-07 |
Roussel Uclaf |
Novel preparation of estradiol and estrone
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
US3865939A
(en)
|
1973-02-23 |
1975-02-11 |
Procter & Gamble |
Edible oils having hypocholesterolemic properties
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
GB1581234A
(en)
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
US5847009A
(en)
|
1986-01-14 |
1998-12-08 |
Alliance Pharmaceutical Corp. |
Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
|
SE8600632D0
(sv)
|
1986-02-13 |
1986-02-13 |
Kabivitrum Ab |
Novel pharmaceutical composition
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
US4938763B1
(en)
|
1988-10-03 |
1995-07-04 |
Atrix Lab Inc |
Biodegradable in-situ forming implants and method of producing the same
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
MY107937A
(en)
|
1990-02-13 |
1996-06-29 |
Takeda Chemical Industries Ltd |
Prolonged release microcapsules.
|
AU2657292A
(en)
|
1991-09-13 |
1993-04-27 |
Cocensys, Inc. |
Novel gabaa receptor with steroid binding sites
|
US5411737A
(en)
|
1991-10-15 |
1995-05-02 |
Merck & Co., Inc. |
Slow release syneresing polymeric drug delivery device
|
JP4008024B2
(ja)
|
1993-05-24 |
2007-11-14 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
Gabaaレセプター複合体と相互作用させるための化合物
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
AU691905B2
(en)
|
1994-02-14 |
1998-05-28 |
Purdue Pharma Ltd. |
Androstanes and pregnanes for allosteric modulation of GABA receptor
|
KR20040068613A
(ko)
|
1994-03-25 |
2004-07-31 |
이소테크니카 인코포레이티드 |
중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
|
AU3125695A
(en)
|
1994-07-21 |
1996-02-22 |
Pharmacia & Upjohn Company |
Neurologically active aminosteroids
|
PT808325E
(pt)
|
1994-11-23 |
2001-06-29 |
Cocensys Inc |
Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba
|
PT837874E
(pt)
|
1995-06-06 |
2005-03-31 |
Euro Celtique Sa |
Esteroides neuroactivos da serie androstano e pregnano
|
US6780853B1
(en)
|
1995-06-06 |
2004-08-24 |
Euro-Celtique S.A. |
Neuroactive steroids of the androstane and pregnane series
|
WO1997003677A1
(en)
|
1995-07-24 |
1997-02-06 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
AU3967297A
(en)
|
1996-08-01 |
1998-02-25 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
DE69730093T2
(de)
|
1996-10-31 |
2006-07-20 |
Takeda Pharmaceutical Co. Ltd. |
Zubereitung mit verzögerter Freisetzung
|
US7630757B2
(en)
|
1997-01-06 |
2009-12-08 |
Flint Hills Scientific Llc |
System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
US6316613B1
(en)
|
1997-07-25 |
2001-11-13 |
Beckman Coulter, Inc. |
Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
|
US6245757B1
(en)
|
1997-10-03 |
2001-06-12 |
Research Corporation Technologies, Inc. |
Use of progestins to treat ischemic event
|
AU756001B2
(en)
*
|
1998-03-11 |
2003-01-02 |
Umecrine Mood Ab |
Epiallopregnanolone in the treatment of CNS disorders
|
US20020198174A1
(en)
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
US20030236236A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
DE60001623T2
(de)
|
1999-12-03 |
2003-12-18 |
Pfizer Prod Inc |
Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
|
US6442887B2
(en)
|
2000-02-25 |
2002-09-03 |
Robert L. Sanquist |
Live bait keeper
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
US6613308B2
(en)
|
2000-09-19 |
2003-09-02 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
US20020072509A1
(en)
*
|
2000-10-11 |
2002-06-13 |
Stein Donald Gerald |
Methods for the treatment of a traumatic central nervous system injury
|
EP1216713A1
(en)
|
2000-12-20 |
2002-06-26 |
Schering Aktiengesellschaft |
Compositions of estrogen-cyclodextrin complexes
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
US7129343B2
(en)
|
2001-02-13 |
2006-10-31 |
University Of Florida |
Bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
EP1392260A2
(en)
|
2001-05-24 |
2004-03-03 |
Alexza Molecular Delivery Corporation |
Delivery of benzodiazepines through an inhalation route
|
AU2002310085B2
(en)
|
2001-05-24 |
2008-09-04 |
Alexza Pharmaceuticals, Inc. |
Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
JP2003063965A
(ja)
*
|
2001-06-13 |
2003-03-05 |
Otsuka Pharmaceut Factory Inc |
注射用シロスタゾール水性製剤
|
US7122593B2
(en)
|
2002-01-14 |
2006-10-17 |
Ansell Healthcare Products Llc |
Magnetically detectable latex articles
|
US7550155B2
(en)
|
2002-07-29 |
2009-06-23 |
Transform Pharmaceuticals Inc. |
Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
|
EP1539183A4
(en)
|
2002-08-28 |
2007-04-25 |
Hollis Eden Pharmaceuticals |
THERAPEUTIC TREATMENT METHODS
|
US9339508B2
(en)
|
2003-01-17 |
2016-05-17 |
Mapreg |
Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
|
EP1626980A4
(en)
|
2003-05-29 |
2007-07-04 |
Univ Washington |
NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
|
WO2005011612A2
(en)
|
2003-07-31 |
2005-02-10 |
The Research Foundation Of State University Of New York |
Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
CN1897942A
(zh)
*
|
2003-12-22 |
2007-01-17 |
先灵公司 |
药用组合物
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
EP1574222B1
(en)
|
2004-03-12 |
2011-02-09 |
Cipla Ltd. |
Sterilization process for steroids
|
US20090118248A1
(en)
|
2004-04-23 |
2009-05-07 |
Euro-Celtique S.A. |
3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
ITMI20041763A1
(it)
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
WO2006037016A2
(en)
|
2004-09-27 |
2006-04-06 |
The Regents Of The University Of California |
Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
US8557861B2
(en)
|
2004-09-28 |
2013-10-15 |
Mast Therapeutics, Inc. |
Low oil emulsion compositions for delivering taxoids and other insoluble drugs
|
EP2471536A1
(en)
|
2004-09-29 |
2012-07-04 |
Harbor BioSciences, Inc. |
Steroid analogs and characterization and treatment methods
|
ATE499109T1
(de)
|
2004-12-07 |
2011-03-15 |
Proteolix Inc |
Zusammensetzung zur proteasomhemmung
|
US20060198896A1
(en)
|
2005-02-15 |
2006-09-07 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
EP1868614B1
(en)
*
|
2005-03-24 |
2012-08-08 |
Emory University |
Dosage regimen for the treatment of a traumatic brain injury with progesterone
|
WO2006110642A2
(en)
|
2005-04-07 |
2006-10-19 |
Hythiam, Inc. |
Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
KR100784860B1
(ko)
|
2005-10-31 |
2007-12-14 |
삼성전자주식회사 |
비휘발성 메모리 장치 및 그 제조 방법
|
KR101405545B1
(ko)
|
2005-11-28 |
2014-07-03 |
마리누스 파마슈티컬스 |
ganaxolone 제형, 이의 제조방법 및 용도
|
TWI376239B
(en)
|
2006-02-01 |
2012-11-11 |
Andrew Xian Chen |
Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
|
US20070287931A1
(en)
|
2006-02-14 |
2007-12-13 |
Dilorenzo Daniel J |
Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス,インコーポレイティド |
4−アシルアミノピリジン誘導体を含む組み合わせ
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20090074677A1
(en)
|
2007-01-08 |
2009-03-19 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
DK2139485T3
(da)
|
2007-04-11 |
2013-01-21 |
Biomarin Pharm Inc |
Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
WO2008154579A1
(en)
*
|
2007-06-11 |
2008-12-18 |
University Of Southern California |
Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
|
JP5663303B2
(ja)
|
2007-06-15 |
2015-02-04 |
リサーチ トライアングル インスティテュート |
Gabaレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
WO2009000038A1
(en)
|
2007-06-28 |
2008-12-31 |
Cnsbio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
EP2254577A1
(en)
|
2007-12-26 |
2010-12-01 |
Eisai R&D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
CN101969953B
(zh)
|
2008-01-03 |
2013-01-09 |
生物马林药物股份有限公司 |
用于治疗bh4反应性疾病的喋呤类似物
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
US8729070B2
(en)
|
2008-02-20 |
2014-05-20 |
Targia Pharmaceuticals |
CNS pharmaceutical compositions and methods of use
|
DE102008015366A1
(de)
|
2008-03-20 |
2009-09-24 |
Merck Patent Gmbh |
Lyophilisierte Nanoemulsion
|
CZ301216B6
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
DK3135672T3
(da)
|
2008-10-10 |
2020-05-04 |
Vm Discovery Inc |
Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
|
CN102300566A
(zh)
|
2008-11-30 |
2011-12-28 |
O·扎查尔 |
血管收缩剂的皮肤应用
|
US20110306579A1
(en)
*
|
2009-01-30 |
2011-12-15 |
Emory University |
Methods of neuroprotection using neuroprotective steroids and a vitamin d
|
US20120142645A1
(en)
|
2009-03-17 |
2012-06-07 |
Marx Christine E |
Neuroactive steroid compositions and methods of use for lowering cholesterol
|
US20110152840A1
(en)
|
2009-12-23 |
2011-06-23 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
BR112012017800B1
(pt)
*
|
2010-01-21 |
2020-12-08 |
Drawbridge Pharmaceuticals Pty Ltd |
composição anestésica ou sedativa
|
BR112013010342A8
(pt)
|
2010-11-03 |
2018-04-03 |
Sanofi Aventis Deutschland |
módulo contendo medicamento e cânula da agulha
|
WO2012075286A2
(en)
|
2010-12-01 |
2012-06-07 |
The Regents Of The University Of California |
Intrapulmonary benzodiazepine for the treatment and prevention of seizures
|
CZ201181A3
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
US9388210B2
(en)
|
2011-02-25 |
2016-07-12 |
Washington University |
Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
FR2973031B1
(fr)
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
US9084797B2
(en)
|
2011-05-23 |
2015-07-21 |
Besins Healthcare Luxembourg Sarl |
Progesterone treatment for improving sleep quality
|
KR20130002292A
(ko)
|
2011-06-28 |
2013-01-07 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
EP2736919A4
(en)
|
2011-07-29 |
2015-01-14 |
Univ California |
NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
|
PT2753632T
(pt)
|
2011-09-08 |
2023-08-17 |
Sage Therapeutics Inc |
Esteróides neuroactivos, composições e respectivas utilizações
|
WO2013043985A1
(en)
|
2011-09-23 |
2013-03-28 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
ES2738526T3
(es)
|
2011-10-14 |
2020-01-23 |
Sage Therapeutics Inc |
Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
|
CA2856592C
(en)
|
2011-11-29 |
2017-05-30 |
Amino Up Chemical Co., Ltd. |
Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent
|
US9492552B2
(en)
|
2011-11-29 |
2016-11-15 |
Jurox Pty Ltd |
Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative
|
PL2806877T3
(pl)
|
2012-01-23 |
2020-06-01 |
Sage Therapeutics, Inc. |
Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
|
US20150175651A1
(en)
|
2012-06-15 |
2015-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2014028398A2
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
KR102121633B1
(ko)
|
2012-08-21 |
2020-06-10 |
세이지 테라퓨틱스, 인크. |
간질 또는 간질지속 상태를 치료하는 방법
|
WO2014058736A1
(en)
|
2012-10-08 |
2014-04-17 |
Washington University |
Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
WO2014071449A1
(en)
|
2012-11-09 |
2014-05-15 |
Goodchild Investments Pty Ltd |
Neuroactive steroids and their use to facilitate neuroprotection
|
JP2016501876A
(ja)
*
|
2012-11-30 |
2016-01-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ステロイドの抗痙攣活性
|
JP6542127B2
(ja)
|
2012-12-18 |
2019-07-10 |
ワシントン・ユニバーシティWashington University |
向神経活性19−アルコキシ−17−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
EP2986624B1
(en)
|
2013-04-17 |
2020-03-25 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids for methods of treatment
|
JP6470258B2
(ja)
|
2013-04-17 |
2019-02-13 |
セージ セラピューティクス, インコーポレイテッド |
19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
US10246482B2
(en)
|
2014-06-18 |
2019-04-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
CA2973140A1
(en)
|
2015-02-06 |
2016-08-11 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
GB2541015A
(en)
|
2015-08-06 |
2017-02-08 |
Ge Oil & Gas Uk Ltd |
Subsea flying lead
|
WO2017066240A1
(en)
|
2015-10-14 |
2017-04-20 |
The Regents Of The University Of California |
Enhancing beta cell replication and/or survival
|
WO2017156103A1
(en)
|
2016-03-08 |
2017-09-14 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
US20180050107A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Neurosteroid compositions and methods of use thereof
|
EP3509585B1
(en)
|
2016-09-07 |
2023-11-01 |
Glia, LLC |
Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
WO2018169798A1
(en)
|
2017-03-11 |
2018-09-20 |
The Regents Of The University Of California |
Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
|
EP3612186A1
(en)
|
2017-04-18 |
2020-02-26 |
Marinus Pharmaceuticals, Inc. |
Sustained release injectable neurosteroid formulations
|
US11752115B2
(en)
|
2017-06-21 |
2023-09-12 |
The Board Of Trustees Of The University Of Illinois |
PPAR-alpha agonist treatment of neuropsychiatric disorders
|
US20200138830A1
(en)
|
2017-06-23 |
2020-05-07 |
The Regents Of The University Of California |
Enhancing gaba's ability to modulate immune responses
|
CA3068462A1
(en)
|
2017-06-23 |
2019-12-27 |
The Board Of Trustees Of The University Of Illinois |
Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
|
WO2019051477A1
(en)
|
2017-09-11 |
2019-03-14 |
Sage Therapeutics, Inc. |
METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
|
EP3681510A1
(en)
|
2017-09-14 |
2020-07-22 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
CA3079259A1
(en)
|
2017-11-10 |
2019-05-16 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating genetic epileptic disorders
|
KR20200096596A
(ko)
|
2017-12-08 |
2020-08-12 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
|
US20220315621A1
(en)
|
2017-12-22 |
2022-10-06 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
BR112020012712A8
(pt)
|
2017-12-22 |
2022-03-03 |
Sage Therapeutics Inc |
Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc
|
EP3737687A1
(en)
|
2018-01-12 |
2020-11-18 |
Sage Therapeutics, Inc. |
Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
|
JP2021523938A
(ja)
|
2018-05-04 |
2021-09-09 |
アセラス ファーマシュウティカルズ コーポレーション |
神経ステロイド誘導体およびその使用
|
CN117959309A
(zh)
|
2018-06-12 |
2024-05-03 |
萨奇治疗股份有限公司 |
19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
AU2019357040A1
(en)
|
2018-10-12 |
2021-05-20 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
|
WO2020082065A1
(en)
|
2018-10-19 |
2020-04-23 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
BR112021010996A2
(pt)
|
2018-12-05 |
2021-08-31 |
Sage Therapeutics, Inc. |
Esteroides neuroativos e seus métodos de uso
|
WO2020132504A1
(en)
|
2018-12-21 |
2020-06-25 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
MX2021014515A
(es)
|
2019-05-31 |
2022-03-22 |
Sage Therapeutics Inc |
Esteroides neuroactivos y composiciones de estos.
|
JP2023504517A
(ja)
|
2019-12-05 |
2023-02-03 |
セージ セラピューティクス, インコーポレイテッド |
19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法
|
EP4121438A2
(en)
|
2020-03-18 |
2023-01-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
PE20221911A1
(es)
|
2020-03-25 |
2022-12-23 |
Sage Therapeutics Inc |
Uso de agentes para el tratamiento de condiciones respiratorias
|
US20230285417A1
(en)
|
2020-07-20 |
2023-09-14 |
Sage Therapeutics, Inc. |
Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|